These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 26905802)

  • 1. Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor.
    Gómara MJ; Sánchez-Merino V; Paús A; Merino-Mansilla A; Gatell JM; Yuste E; Haro I
    Biochim Biophys Acta; 2016 Jun; 1860(6):1139-48. PubMed ID: 26905802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A cyclic GB virus C derived peptide with anti-HIV-1 activity targets the fusion peptide of HIV-1.
    Galatola R; Vasconcelos A; Pérez Y; Cruz A; Pujol M; Alsina MA; Gómara MJ; Haro I
    Eur J Med Chem; 2014 Oct; 86():589-604. PubMed ID: 25218908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural Study of a New HIV-1 Entry Inhibitor and Interaction with the HIV-1 Fusion Peptide in Dodecylphosphocholine Micelles.
    Pérez Y; Gómara MJ; Yuste E; Gómez-Gutierrez P; Pérez JJ; Haro I
    Chemistry; 2017 Aug; 23(48):11703-11713. PubMed ID: 28677862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV-1 inhibiting capacity of novel forms of presentation of GB virus C peptide domains is enhanced by coordination to gold compounds.
    Gómara MJ; Galatola R; Gutiérrez A; Gimeno MC; Gatell JM; Sánchez-Merino V; Yuste E; Haro I
    Curr Med Chem; 2014; 21(2):238-50. PubMed ID: 24083612
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GB virus type C interactions with HIV: the role of envelope glycoproteins.
    Mohr EL; Stapleton JT
    J Viral Hepat; 2009 Nov; 16(11):757-68. PubMed ID: 19758271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthetic peptides derived from an N-terminal domain of the E2 protein of GB virus C in the study of GBV-C/HIV-1 co-infection.
    Fernández L; Chan WC; Egido M; Gómara MJ; Haro I
    J Pept Sci; 2012 May; 18(5):326-35. PubMed ID: 22438139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthetic peptides of hepatitis G virus (GBV-C/HGV) in the selection of putative peptide inhibitors of the HIV-1 fusion peptide.
    Herrera E; Gomara MJ; Mazzini S; Ragg E; Haro I
    J Phys Chem B; 2009 May; 113(20):7383-91. PubMed ID: 19402654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of synthetic peptides belonging to E2 envelope protein of GB virus C on human immunodeficiency virus type 1 infection.
    Herrera E; Tenckhoff S; Gómara MJ; Galatola R; Bleda MJ; Gil C; Ercilla G; Gatell JM; Tillmann HL; Haro I
    J Med Chem; 2010 Aug; 53(16):6054-63. PubMed ID: 20718496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peptides derived from a distinct region of GB virus C glycoprotein E2 mediate strain-specific HIV-1 entry inhibition.
    Koedel Y; Eissmann K; Wend H; Fleckenstein B; Reil H
    J Virol; 2011 Jul; 85(14):7037-47. PubMed ID: 21543477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV-1 fusion is blocked through binding of GB Virus C E2-derived peptides to the HIV-1 gp41 disulfide loop [corrected].
    Eissmann K; Mueller S; Sticht H; Jung S; Zou P; Jiang S; Gross A; Eichler J; Fleckenstein B; Reil H
    PLoS One; 2013; 8(1):e54452. PubMed ID: 23349893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV entry inhibition by the envelope 2 glycoprotein of GB virus C.
    Jung S; Eichenmüller M; Donhauser N; Neipel F; Engel AM; Hess G; Fleckenstein B; Reil H
    AIDS; 2007 Mar; 21(5):645-7. PubMed ID: 17314528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GB virus type C envelope protein E2 elicits antibodies that react with a cellular antigen on HIV-1 particles and neutralize diverse HIV-1 isolates.
    Mohr EL; Xiang J; McLinden JH; Kaufman TM; Chang Q; Montefiori DC; Klinzman D; Stapleton JT
    J Immunol; 2010 Oct; 185(7):4496-505. PubMed ID: 20826757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chimpanzee GB virus C and GB virus A E2 envelope glycoproteins contain a peptide motif that inhibits human immunodeficiency virus type 1 replication in human CD4⁺ T-cells.
    McLinden JH; Stapleton JT; Klinzman D; Murthy KK; Chang Q; Kaufman TM; Bhattarai N; Xiang J
    J Gen Virol; 2013 Apr; 94(Pt 4):774-782. PubMed ID: 23288422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of HIV-1 resistance to a fusion inhibitor, N36, derived from the gp41 amino-terminal heptad repeat.
    Izumi K; Nakamura S; Nakano H; Shimura K; Sakagami Y; Oishi S; Uchiyama S; Ohkubo T; Kobayashi Y; Fujii N; Matsuoka M; Kodama EN
    Antiviral Res; 2010 Aug; 87(2):179-86. PubMed ID: 20438763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surface behavior of peptides from E1 GBV-C protein: Interaction with anionic model membranes and importance in HIV-1 FP inhibition.
    Galatola R; Cruz A; Gómara MJ; Prat J; Alsina MA; Haro I; Pujol M
    Biochim Biophys Acta; 2015 Feb; 1848(2):392-407. PubMed ID: 25450346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of HIV-1 fusion peptide inhibition by synthetic peptides from E1 protein of GB virus C.
    Sánchez-Martín MJ; Hristova K; Pujol M; Gómara MJ; Haro I; Alsina MA; Busquets MA
    J Colloid Interface Sci; 2011 Aug; 360(1):124-31. PubMed ID: 21565353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hydrophobic mutations in buried polar residues enhance HIV-1 gp41 N-terminal heptad repeat-C-terminal heptad repeat interactions and C-peptides' anti-HIV activity.
    Zheng B; Wang K; Lu L; Yu F; Cheng M; Jiang S; Liu K; Cai L
    AIDS; 2014 Jun; 28(9):1251-60. PubMed ID: 24625369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide.
    Münch J; Ständker L; Adermann K; Schulz A; Schindler M; Chinnadurai R; Pöhlmann S; Chaipan C; Biet T; Peters T; Meyer B; Wilhelm D; Lu H; Jing W; Jiang S; Forssmann WG; Kirchhoff F
    Cell; 2007 Apr; 129(2):263-75. PubMed ID: 17448989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liposome destabilization induced by synthetic lipopeptides corresponding to envelope and non-structural domains of GBV-C/HGV virus. Conformational requirements for leakage.
    Fernández-Vidal M; Rojo N; Herrera E; Gómara MJ; Haro I
    Biophys Chem; 2008 Jan; 132(1):55-63. PubMed ID: 17988786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peptide Assembly on the Membrane Determines the HIV-1 Inhibitory Activity of Dual-Targeting Fusion Inhibitor Peptides.
    Gomara MJ; Perez Y; Martinez JP; Barnadas-Rodriguez R; Schultz A; von Briesen H; Peralvarez-Marin A; Meyerhans A; Haro I
    Sci Rep; 2019 Mar; 9(1):3257. PubMed ID: 30824796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.